The 2017 Hormone Therapy Position Statement of The North American Menopause Society

The North American Menopause Society 2017 Hormone Therapy Position Statement Advisory Panel

Disclosures

The North American Menopause Society (NAMS). 2018;24(7):728-753. 

In This Article

Economic Considerations

Greater severity of VMS is associated with lower levels of health status and work productivity and greater use of health resources.[42,270,271] The greatest benefit-risk ratio from pharmacoeconomic analyses in younger women[272] and those from the WHI[273] has been found for the use of HT for menopause-associated VMS,[274] particularly in women who have had a hysterectomy who can use ET.[275]

Key Points

  • Potential reduced costs by treating VMS and related symptoms or preventing bone fractures should be evaluated in the context of evaluation and treatment of AEs and costs of HT medications.

  • Initiation of HT closer to menopause onset increased quality-adjusted life-years and was highly cost-effective compared with initiating HT in women aged older than 65 years.

  • Indirect economic costs for menopausal women include effects on QOL, work productivity, healthcare resource use, and the potential costs of women who have had a hysterectomy not receiving HT.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....